JPS6124374B2 - - Google Patents
Info
- Publication number
- JPS6124374B2 JPS6124374B2 JP57086379A JP8637982A JPS6124374B2 JP S6124374 B2 JPS6124374 B2 JP S6124374B2 JP 57086379 A JP57086379 A JP 57086379A JP 8637982 A JP8637982 A JP 8637982A JP S6124374 B2 JPS6124374 B2 JP S6124374B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- difluoro
- biphenyl
- salt
- oxypropionic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000000202 analgesic effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- SZWWLSFFGGWCCC-UHFFFAOYSA-N 2-[4-(2,4-difluorophenyl)phenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1C1=CC=C(F)C=C1F SZWWLSFFGGWCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- -1 ester compound Chemical class 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- ASOVDRYKVVVCIA-UHFFFAOYSA-N 4-(2,4-difluorophenyl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC=C(F)C=C1F ASOVDRYKVVVCIA-UHFFFAOYSA-N 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 150000002169 ethanolamines Chemical class 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 3
- 208000012895 Gastric disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 150000008545 L-lysines Chemical class 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, Oâmetal, âCHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
æ¬çºæã¯ãæ°èŠãªãªãã·ããããªã³é
žèªå°äœã
ãã®è£œé æ³ããã³ãããæå¹æåãšããé®çæ¶ç
å€ã«é¢ãããããã«è©³ããã¯ãæ¬çºæã¯åŒ
ïŒïŒïŒ ã§è¡šããããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããš
ãã«ïŒâãªãã·ããããªã³é žããã®è£œé æ³ããã³
ãããæå¹æåãšããé®çæ¶çå€ã«é¢ããã æ¬çºæã®ååç©ã«ã¯åŒïŒïŒã§è¡šãããããªã
ã·ããããªã³é žèªå°äœã®ã»ãã«ããããšè¬çåŠç
ã«èš±å®¹ãããéå±ã€ãªã³ïŒããšãã°ãããªãŠã ã€
ãªã³ãã«ãªãŠã ã€ãªã³ããã°ãã·ãŠã ã€ãªã³ãã«
ã«ã·ãŠã ã€ãªã³ãªã©ïŒãŸãã¯è¬çåŠçã«èš±å®¹ãã
ãææ©å¡©åºïŒããšãã°ãªãžã³ãã¢ã«ã®ãã³ããžãš
ã¿ããŒã«ã¢ãã³ãªã©ïŒãšã®å¡©ãå«ãŸãããããã
æ¬çºæã®ååç©ããã³ãã®å¡©ã¯ããããæçç掻
æ§ããã³é®ç掻æ§ãæãããã€èé害ãçããã
ãããšããªãã åŒïŒïŒã§è¡šããããæ¬çºæã®ååç©ã®è£œé æ³
ã«ãããåå¿ã¯ãã€ãã®åå¿åŒã«ãããã€ãŠé²è¡
ããã ããªãã¡åŒïŒïŒã§è¡šããããïŒâïŒ2â²ïŒ4â²â
ãžãã«ãªãããšãã«ïŒããšããŒã«ã®ãããªãŠã å¡©
ãšåŒïŒïŒã§è¡šããããããã¢ããããªã³é žãšã
ã«ãšãåå¿ãããã€ãã§ããããåŒïŒïŒã§è¡šã
ããããšã¹ãã«ååç©ãå æ°Žå解ããããšã«ã
ããåŒïŒïŒã§è¡šããããååç©ããããååç©
ïŒïŒãšååç©ïŒïŒãšã®åå¿ã¯äœçŽã¢ã«ã³ãŒ
ã«ããã奜ãŸããã¯ãšã¿ããŒã«äžã§è¡ãªãããã
ãŸãååç©ïŒïŒã¯åå¿ã«äŸããçŽåã«èª¿æŽããŠ
ããããšã奜ãŸãããåŒïŒïŒã§è¡šãããããšã¹
ãã«ååç©ã®å æ°Žå解ã¯æªç²Ÿè£œã®ãŸãŸãã¢ã«ã«ãª
éå±æ°Žé žåç©ã®æ°Žæº¶æ¶²äžã§çŽæ¥è¡ãªãããšãã§ã
ãããããŠãã®å æ°Žå解åå¿æ¶²ãããªãã¡åŒ
ïŒïŒã§è¡šããããååç©ã®å¡©ã®æº¶æ¶²ãç¡æ©é žã§
é žæ§ã«ããããšã«ãããååç©ïŒïŒãããã
ãã ã€ãã«å®æœäŸããããŠæ¬çºæã®ãªãã·ããããª
ã³é žèªå°äœããã³ãã®è£œé æ³ããã詳现ã«èª¬æã
ãããæ¬çºæã¯ãããã®å®æœäŸã®ã¿ã«éå®ããã
ãã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒåŒïŒïŒã§è¡šããããååç©ã®è£œé ïŒ 100ml容ã®ãã©ã¹ã³ã«ç¡æ°Žãšã¿ããŒã«30mlãå
ããéå±ãããªãŠã 0.22ïœãå ããŠæº¶è§£ãããã
éå±ãããªãŠã ãå®å šã«æº¶è§£ããã®ã¡ãïŒâ
ïŒ2â²ïŒ4â²âãžãã«ãªãããšãã«ïŒããšããŒã«ïŒïœ
ãšãããã¢ããããªã³é žãšãã«1.5mlãå ããã
åå¿æ¶²ãïŒæééæµãããã®ã®ã¡æº¶åªãæžå§äžã«
ãŠçå»ãããæ®æž£ã«10ïŒ NaOH30mlãå ããïŒæ
ééæµãããå·åŽåŸãåžå¡©é žæº¶æ¶²ã§é žæ§ã«ããã
ãããæ²æ®¿ç©ãåžåŒéãããšãã«ãšãŒãã«ãšïœ
âãããµã³ã®æ··å溶åªããåçµæ¶ãããããããŠ
åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°äœ
1.9ïœïŒåç74ïŒ ïŒãããããã®ååç©ã®èç¹ã¯
153ã155âã§ãããé«æž©ã®äœçŽã¢ã«ã³ãŒã«ã«å¯æº¶
ã§ããããå¡©çŽ åçåæ°ŽçŽ ããã³æ°Žã«äžæº¶ã§ãã€
ãã å çŽ åæå€ïŒC15H12F12O3 ïŒååé278.24ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC64.74 H4.35 å®æž¬å€ïŒïŒ ïŒïŒC64.49 H4.38 IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1600ïŒ1705ïŒ1715 ïŒHâNMRã¹ãã¯ãã«ïŒÎŽå€ïŒppmïŒïŒ ïŒå éšåºæºïŒTMSã溶åªïŒDMSOâd6ïŒ 1.55ïŒïœïŒ3HïŒCH3ïŒïŒ4.85ïŒïŒïŒ1HïŒ
âCHâïŒïŒ6.8ã7.7ïŒïœïŒ7Hãè³éŠç°æ°Ž
çŽ ååããã³1HïŒã¢ãŒãã«ïŒïŒ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°
äœã¯ä»¥äžã笊å·MR714ã§è¡šããããã®èªå°äœã¯
éåžžã®æ¹æ³ã§ãã®å¡©ã調æŽããããã«çšããã
ãã以äžã«èª¬æããå®æœäŸã¯åŒïŒïŒã§è¡šããã
ãé žã®å¡©ã®ãã¡ã®æ°åã«ã€ããã®èª¿è£œãšç¹æ§ã説
æãããã®ã§ããããæ¬çºæã®å¡©ã¯ãããå®æœäŸ
ã®ã¿ã«éå®ããããã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ãããªãŠã å¡©ã®è£œé ïŒ ãšã¿ããŒã«250mlã«äžè¬åŒïŒïŒã§è¡šãããã
ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâãªãã·
ããããªã³é ž25ïœïŒ90ããªã¢ã«ïŒãå ãããã®æº¶
液ãå æž©ãããããªãŠã ã¡ããã·ã4.86ïœïŒ90ã
ãªã¢ã«ïŒãå ãããé«æž©æº¶æ¶²ã«ããããããçµæ¶
æ²æ®¿ç©ãæåºããå·åŽãããšã«ããæåºãå®äºã
ããæ°Žããåçµæ¶ããããšã«ããååç©ïŒïŒã®
ãããªãŠã å¡©22ïœããããããèç¹ã¯258ã261â
ïŒå解ïŒã§ãã€ãã å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ã«ã«ã·ãŠã å¡©ã®è£œé æ³ïŒ ååç©ïŒïŒ50ïœïŒ180ããªã¢ã«ïŒãš
NaHCO315ïœïŒ180ããªã¢ã«ïŒã300ccã®æ°Žã«æº¶è§£
ãããŠå æž©ããããã«æ°Ž80mlã«å¡©åã«ã«ã·ãŠã
10.7ïœïŒ90ããªã¢ã«ïŒã溶解ãããé«æž©æº¶æ¶²ãå
ãããå·åŽããããšã«ããçµæ¶æ§ã®æ²æ®¿ç©ããã
ããããã®æ²æ®¿ç©ã®åæããŒã¿ã¯ã€ãã®åŒã§è¡šã
ãããååç©ãšäžèŽããã ãã®ç©è³ªã¯æž©åºŠ286â以äžã§å解ãã€ã€è解ã
ãã IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1045ïŒ1250ïŒ1590ïŒ1600 å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ãšã¿ããŒã«ã¢ãã³å¡©ã®è£œ
é ïŒ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°
äœ50ïœïŒ90ããªã¢ã«ïŒãé ¢é žãšãã«250mlã«å æž©
ããªãã溶解ãããããã®æº¶æ¶²ã«ãšã¿ããŒã«ã¢ã
ã³11ïœïŒ90ããªã¢ã«ïŒãå ãããé«æž©æº¶æ¶²ã«ãã
ããããéšåçã«æ²æ®¿ããå¡©ãåããçŽäžã§
ïŒåç®ã¯é ¢é žãšãã«ãïŒåç®ã¯ãžãšãã«ãšãŒãã«
ã«ããæŽæµããã57ïœã®çµæ¶æ§åºåœ¢ç©ãããã
ãããã®èç¹ã¯125âã127âã§ãã€ãã å çŽ åæå€ïŒC17H19F2NO4 ïŒååé339.33ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC56.63 H5.70 N4.13 å®æž¬å€ïŒïŒ ïŒïŒC56.56 H5.78 N4.02 IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1050ïŒå¯Ÿç§°äŒžçž®ïŒ£âïŒã1235ïŒé察称
䌞瞮ïŒïŒ£ïŒã1610ïŒäŒžçž®ïŒ£ïŒïŒ¯ïŒã2750ã
2600ïŒäŒžçž®+NâïŒã3450ã3200ïŒäŒžçž®ïŒ¯
âïŒšïŒ ïŒHâNMRã¹ãã¯ãã«ïŒÎŽå€ïŒppmïŒïŒ
ïŒå éšåºæºïŒTMSã溶åªïŒCDOl3ïŒ
ïŒCD3ïŒ2SO 50ïŒ50ïŒ 1.5ïŒïœïŒ3HïŒCHâCH3ïŒïŒ2.7ãïŒ
ïŒïœïŒ2HïŒCH2âOHïŒïŒ4.5ïŒïœïŒ1HïŒ
CH.âCH3ïŒïŒ6.5ã7.3ïŒïœïŒ11Hãè³éŠç°
æ°ŽçŽ åå7HïŒ4Hã¢ãŒãã«ïŒ å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ïŒ¬âãªãžã³å¡©ïŒ åºçºç©è³ªãšããŠãšã¿ããŒã«ã¢ãã³ã®ãããã«ïŒ¬
âãªãžã³ãçšããã»ãã¯å®æœäŸïŒãšåæ§ã®æ¹æ³ã«
ããâãªãžã³å¡©ããããèç¹ã¯193ã196âã§ã
ã€ãã å çŽ åæå€ïŒC21H26F2N2O5ïŒååé424.43
ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC59.42 H6.17 N6.60 å®æž¬å€ïŒïŒ ïŒïŒC59.38 H6.23 N6.44 ïŒé®ç掻æ§ïŒ é®ç掻æ§ã¯ããŠã¹ãçšããããšãã«ããã³ã«ã
ãèªçºãããæ©è»¢è©Šéšã«ãã調ã¹ããããšãã«ã
ãã³æäžå30åã«å®éšåç©ã«å¯ŸãMR714ã®25
mgïŒKgäœéãçµå£æäžãããå¯Ÿç §äŸãšããŠã¢ã»ã
ã«ãµãªãã«é žãã€ãããããšã³ããã©ã»ã¿ã¢ãŒã«
ïŒïœâã¢ã»ãã«ã¢ããããšããŒã«ïŒããã³ãžãã«
ãã¶ãŒã«ïŒdifunisalïŒã第ïŒè¡šã«ç€ºãæäžéã§æ
äžããã ããããçµæã第ïŒè¡šã«ç€ºãã MR714ã®é®ç掻æ§ã¯å®è³ªçã«ãžãã«ãã¶ãŒã«
ãšåçã§ãããæäžéãšããŠïŒåéãçšãããã©
ã»ã¿ã¢ãŒã«ããå®è³ªçã«ããããŠãããŸã10åé
ãçšããã¢ã»ãã«ãµãªãã«é žããã³ïŒåéãçšã
ãã€ãããããšã³ãšãã®æŽ»æ§ãå®è³ªçã«åãã§ã
ãé«ãé®ç掻æ§ãæããããšãå€æããã ïŒæçç掻æ§ïŒ è©Šéšã¯ã©ãããçšãMR714ã®25mgïŒKgäœéçµ
å£æäžãããå¯Ÿç §äŸãšããŠã¢ã»ãã«ãµãªãã«é žã
ã€ãããããšã³ããã©ã»ã¿ã¢ãŒã«ããã³ãžãã«ã
ã¶ãŒã«ãçšãããæäž30ååŸãã«ã©ã²ãã³ãµãã
ã©ã³ã¿ïŒsubplantarïŒæ³šå°ã«ãã浮皮ãå®éšåç©
ã®å³è¶³ã«çãããããã®ççéšåã®äœç©ãïŒæé
ããšã«ïŒæéã«ãããèšé²ããã ããããçµæã第ïŒè¡šã«ç€ºãã ãã®çµæãMR714ãããããæçç掻æ§ãæ
ããããšãå€æããã ïŒèèæ§è©ŠéšïŒ æççéã¹ããã€ãå€ã®å€ããèç²èã«é害ã
ã²ããããããšããMR714ã®èèæ§è©Šéšãå®æœ
ããã 18æé絶é£ãããã©ããã«MR714ãçµå£æäž
ããå¯Ÿç §äŸãšããŠã¢ã»ãã«ãµãªãã«é žãã€ããã
ããšã³ããã©ã»ã¿ã¢ãŒã«ããã³ãžãã«ãã¶ãŒã«ã
çšããã æäžéãšããããçµæã第ïŒè¡šã«ç€ºãã æäžïŒæéåŸã®çµæããMR714ã¯èç²èã«å¯Ÿ
ããŠååãªèæ§ãããããšãå€æããã第ïŒè¡šã
ããMR714ã¯å®è³ªçã«èé害ãæ¹ãèµ·ããã察
ç §äŸãšæ¯èŒããŠããã®çšåºŠãããªãäœãããšãã
ããã ïŒæ¥æ§æ¯æ§è©ŠéšïŒ MR714ã¯ã»ãšãã©æ¥æ§æ¯æ§ããªãããšãå€æ
ãããããŠã¹ã«å¯ŸããŠçµå£æäžããŠè¡ãªã€ãæ¥æ§
æ¯æ§è©Šéšã«ãããŠãDL50ã¯840mgïŒKgäœéã§ãã€
ãã ïŒè¬çåŠè©Šéšããã³ä»£è¬ïŒ è©Šéšã¯ã©ãããçšããŠè¡ãªãã25ïŒ50ããã³
100mgïŒKgäœéã®MR714ãçµå£æäžãããè¡æŒ¿äž
ã®MR714ã®æ¿åºŠãå¢å ããæäžåŸïŒæéãªãã
ïŒæéã§æåã®ããŒã¯ã«å¯ŸããããããŠãã®æ¿åºŠ
ã次第ã«äœäžãã第ïŒã®ããŒã¯ãçŸãããã50ãª
ãã100mgïŒKgæäžããã°ããã«ã¯24æéæç¶ã
ãé·æéã®ãã©ãïŒplateauïŒããŒã¯ãçãã
ãã25mgïŒKgäœéæäžããå Žåã«ã¯ç¬¬ïŒã®ããŒã¯
ã¯çæéã§æ¶æ» ããã è¡æŒ¿äžã«ãããåæžæã¯13æéã§ãããããã¯
ä»ã®æççéã¹ããã€å€ãšæ¯èŒããŠé«ãæ°å€ã§ã
ãããŸãå¯Ÿç §äŸãšæ¯èŒããŠããžãã«ãã¶ãŒã«ã®å
æžæïŒæäžéãåãã§ããã°ããïŒã®ïŒå匷ã§ã
ããããMR714ã®æçšéã¯ïŒæ¥ïŒåã§é©åœã§ã
ãã èèµãè èµãèºããã³åå®®ã«ãããæ¿åºŠã¯è¡æŒ¿
äžã«ãããæ¿åºŠãšæ¯èŒããŠäœããç°ãªãæ æ§ã瀺
ãããããããªãããè¡æŒ¿ãšåå®®ã®æ¿åºŠæ¯ã¯0.34
ã§ããããªãé«ãæ°å€ã§ããã ïŒååç©ïŒïŒããã³ãã®å¡©ã®è£œå€æ³ïŒ çµå£ãããã¯éçµå£æäžãããæ¬çºæã®å»è¬çµ
æç©ã®ããã¡ãšããŠã¯ãããšãã°æ¡æ£å¯èœãªãã
ããã¯å è£ çŽã«ããããã±ãŒãžå¯èœãªé å€ãã«ã
ã»ã«ãç²æ«ãªã©ãé©åœã§ããã泚å°è¬ãšããŠãã
ã¢ãŒã«ïŒphthialsïŒãé©åœã§ããã 以äžã«åŠæ¹äŸããããŠèª¬æãããæ¬çºæã¯ãã
ãã®åŠæ¹äŸã®ã¿ã«éå®ããããã®ã§ã¯ãªãã åŠæ¹äŸ ïœ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é ž250mgã«è£œè¬æ¥çã§äžè¬ã«
çšããããŠãã賊圢å€ãšæ¡æ£å€ãé åãé å€ãš
ããã ïœ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèª
å°äœ375mgã«äžè¿°ã®è³Šåœ¢å€ãšæ¡æ£å€ãæ·»å ãé
å€ãšããã ïœ èŠªæ¶²æ§ã§ããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâã
ããšãã«ïŒâãªãã·ããããªã³é žã®ãªãžã³å¡©400
mgã«çèå 泚å°çšã®æº¶åªãšããŠçŽ3ccã®ããã¢
ãŒã«ãå ããŠæ³šå°æ¶²ãšããã ïŒäººäœã«å¯Ÿããæå¹æäžéïŒ æ¬çºæã®ååç©ã¯æ人æ£è ã«ïŒæ¥ããã250ã
750mgæäžå¯èœã§ãããããªãã¡250mgã®é å€ãïŒ
æ¥ãããïŒãªããïŒããããã¯375mgã®é å€ãïŒ
æ¥ãããïŒãªããïŒæäžå¯èœã§ããã
ãã®è£œé æ³ããã³ãããæå¹æåãšããé®çæ¶ç
å€ã«é¢ãããããã«è©³ããã¯ãæ¬çºæã¯åŒ
ïŒïŒïŒ ã§è¡šããããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããš
ãã«ïŒâãªãã·ããããªã³é žããã®è£œé æ³ããã³
ãããæå¹æåãšããé®çæ¶çå€ã«é¢ããã æ¬çºæã®ååç©ã«ã¯åŒïŒïŒã§è¡šãããããªã
ã·ããããªã³é žèªå°äœã®ã»ãã«ããããšè¬çåŠç
ã«èš±å®¹ãããéå±ã€ãªã³ïŒããšãã°ãããªãŠã ã€
ãªã³ãã«ãªãŠã ã€ãªã³ããã°ãã·ãŠã ã€ãªã³ãã«
ã«ã·ãŠã ã€ãªã³ãªã©ïŒãŸãã¯è¬çåŠçã«èš±å®¹ãã
ãææ©å¡©åºïŒããšãã°ãªãžã³ãã¢ã«ã®ãã³ããžãš
ã¿ããŒã«ã¢ãã³ãªã©ïŒãšã®å¡©ãå«ãŸãããããã
æ¬çºæã®ååç©ããã³ãã®å¡©ã¯ããããæçç掻
æ§ããã³é®ç掻æ§ãæãããã€èé害ãçããã
ãããšããªãã åŒïŒïŒã§è¡šããããæ¬çºæã®ååç©ã®è£œé æ³
ã«ãããåå¿ã¯ãã€ãã®åå¿åŒã«ãããã€ãŠé²è¡
ããã ããªãã¡åŒïŒïŒã§è¡šããããïŒâïŒ2â²ïŒ4â²â
ãžãã«ãªãããšãã«ïŒããšããŒã«ã®ãããªãŠã å¡©
ãšåŒïŒïŒã§è¡šããããããã¢ããããªã³é žãšã
ã«ãšãåå¿ãããã€ãã§ããããåŒïŒïŒã§è¡šã
ããããšã¹ãã«ååç©ãå æ°Žå解ããããšã«ã
ããåŒïŒïŒã§è¡šããããååç©ããããååç©
ïŒïŒãšååç©ïŒïŒãšã®åå¿ã¯äœçŽã¢ã«ã³ãŒ
ã«ããã奜ãŸããã¯ãšã¿ããŒã«äžã§è¡ãªãããã
ãŸãååç©ïŒïŒã¯åå¿ã«äŸããçŽåã«èª¿æŽããŠ
ããããšã奜ãŸãããåŒïŒïŒã§è¡šãããããšã¹
ãã«ååç©ã®å æ°Žå解ã¯æªç²Ÿè£œã®ãŸãŸãã¢ã«ã«ãª
éå±æ°Žé žåç©ã®æ°Žæº¶æ¶²äžã§çŽæ¥è¡ãªãããšãã§ã
ãããããŠãã®å æ°Žå解åå¿æ¶²ãããªãã¡åŒ
ïŒïŒã§è¡šããããååç©ã®å¡©ã®æº¶æ¶²ãç¡æ©é žã§
é žæ§ã«ããããšã«ãããååç©ïŒïŒãããã
ãã ã€ãã«å®æœäŸããããŠæ¬çºæã®ãªãã·ããããª
ã³é žèªå°äœããã³ãã®è£œé æ³ããã詳现ã«èª¬æã
ãããæ¬çºæã¯ãããã®å®æœäŸã®ã¿ã«éå®ããã
ãã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒåŒïŒïŒã§è¡šããããååç©ã®è£œé ïŒ 100ml容ã®ãã©ã¹ã³ã«ç¡æ°Žãšã¿ããŒã«30mlãå
ããéå±ãããªãŠã 0.22ïœãå ããŠæº¶è§£ãããã
éå±ãããªãŠã ãå®å šã«æº¶è§£ããã®ã¡ãïŒâ
ïŒ2â²ïŒ4â²âãžãã«ãªãããšãã«ïŒããšããŒã«ïŒïœ
ãšãããã¢ããããªã³é žãšãã«1.5mlãå ããã
åå¿æ¶²ãïŒæééæµãããã®ã®ã¡æº¶åªãæžå§äžã«
ãŠçå»ãããæ®æž£ã«10ïŒ NaOH30mlãå ããïŒæ
ééæµãããå·åŽåŸãåžå¡©é žæº¶æ¶²ã§é žæ§ã«ããã
ãããæ²æ®¿ç©ãåžåŒéãããšãã«ãšãŒãã«ãšïœ
âãããµã³ã®æ··å溶åªããåçµæ¶ãããããããŠ
åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°äœ
1.9ïœïŒåç74ïŒ ïŒãããããã®ååç©ã®èç¹ã¯
153ã155âã§ãããé«æž©ã®äœçŽã¢ã«ã³ãŒã«ã«å¯æº¶
ã§ããããå¡©çŽ åçåæ°ŽçŽ ããã³æ°Žã«äžæº¶ã§ãã€
ãã å çŽ åæå€ïŒC15H12F12O3 ïŒååé278.24ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC64.74 H4.35 å®æž¬å€ïŒïŒ ïŒïŒC64.49 H4.38 IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1600ïŒ1705ïŒ1715 ïŒHâNMRã¹ãã¯ãã«ïŒÎŽå€ïŒppmïŒïŒ ïŒå éšåºæºïŒTMSã溶åªïŒDMSOâd6ïŒ 1.55ïŒïœïŒ3HïŒCH3ïŒïŒ4.85ïŒïŒïŒ1HïŒ
âCHâïŒïŒ6.8ã7.7ïŒïœïŒ7Hãè³éŠç°æ°Ž
çŽ ååããã³1HïŒã¢ãŒãã«ïŒïŒ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°
äœã¯ä»¥äžã笊å·MR714ã§è¡šããããã®èªå°äœã¯
éåžžã®æ¹æ³ã§ãã®å¡©ã調æŽããããã«çšããã
ãã以äžã«èª¬æããå®æœäŸã¯åŒïŒïŒã§è¡šããã
ãé žã®å¡©ã®ãã¡ã®æ°åã«ã€ããã®èª¿è£œãšç¹æ§ã説
æãããã®ã§ããããæ¬çºæã®å¡©ã¯ãããå®æœäŸ
ã®ã¿ã«éå®ããããã®ã§ã¯ãªãã å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ãããªãŠã å¡©ã®è£œé ïŒ ãšã¿ããŒã«250mlã«äžè¬åŒïŒïŒã§è¡šãããã
ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâãªãã·
ããããªã³é ž25ïœïŒ90ããªã¢ã«ïŒãå ãããã®æº¶
液ãå æž©ãããããªãŠã ã¡ããã·ã4.86ïœïŒ90ã
ãªã¢ã«ïŒãå ãããé«æž©æº¶æ¶²ã«ããããããçµæ¶
æ²æ®¿ç©ãæåºããå·åŽãããšã«ããæåºãå®äºã
ããæ°Žããåçµæ¶ããããšã«ããååç©ïŒïŒã®
ãããªãŠã å¡©22ïœããããããèç¹ã¯258ã261â
ïŒå解ïŒã§ãã€ãã å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ã«ã«ã·ãŠã å¡©ã®è£œé æ³ïŒ ååç©ïŒïŒ50ïœïŒ180ããªã¢ã«ïŒãš
NaHCO315ïœïŒ180ããªã¢ã«ïŒã300ccã®æ°Žã«æº¶è§£
ãããŠå æž©ããããã«æ°Ž80mlã«å¡©åã«ã«ã·ãŠã
10.7ïœïŒ90ããªã¢ã«ïŒã溶解ãããé«æž©æº¶æ¶²ãå
ãããå·åŽããããšã«ããçµæ¶æ§ã®æ²æ®¿ç©ããã
ããããã®æ²æ®¿ç©ã®åæããŒã¿ã¯ã€ãã®åŒã§è¡šã
ãããååç©ãšäžèŽããã ãã®ç©è³ªã¯æž©åºŠ286â以äžã§å解ãã€ã€è解ã
ãã IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1045ïŒ1250ïŒ1590ïŒ1600 å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ãšã¿ããŒã«ã¢ãã³å¡©ã®è£œ
é ïŒ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèªå°
äœ50ïœïŒ90ããªã¢ã«ïŒãé ¢é žãšãã«250mlã«å æž©
ããªãã溶解ãããããã®æº¶æ¶²ã«ãšã¿ããŒã«ã¢ã
ã³11ïœïŒ90ããªã¢ã«ïŒãå ãããé«æž©æº¶æ¶²ã«ãã
ããããéšåçã«æ²æ®¿ããå¡©ãåããçŽäžã§
ïŒåç®ã¯é ¢é žãšãã«ãïŒåç®ã¯ãžãšãã«ãšãŒãã«
ã«ããæŽæµããã57ïœã®çµæ¶æ§åºåœ¢ç©ãããã
ãããã®èç¹ã¯125âã127âã§ãã€ãã å çŽ åæå€ïŒC17H19F2NO4 ïŒååé339.33ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC56.63 H5.70 N4.13 å®æž¬å€ïŒïŒ ïŒïŒC56.56 H5.78 N4.02 IRã¹ãã¯ãã«ïŒcm-1ïŒïŒïŒããžãšãŒã«ïŒ 1050ïŒå¯Ÿç§°äŒžçž®ïŒ£âïŒã1235ïŒé察称
䌞瞮ïŒïŒ£ïŒã1610ïŒäŒžçž®ïŒ£ïŒïŒ¯ïŒã2750ã
2600ïŒäŒžçž®+NâïŒã3450ã3200ïŒäŒžçž®ïŒ¯
âïŒšïŒ ïŒHâNMRã¹ãã¯ãã«ïŒÎŽå€ïŒppmïŒïŒ
ïŒå éšåºæºïŒTMSã溶åªïŒCDOl3ïŒ
ïŒCD3ïŒ2SO 50ïŒ50ïŒ 1.5ïŒïœïŒ3HïŒCHâCH3ïŒïŒ2.7ãïŒ
ïŒïœïŒ2HïŒCH2âOHïŒïŒ4.5ïŒïœïŒ1HïŒ
CH.âCH3ïŒïŒ6.5ã7.3ïŒïœïŒ11Hãè³éŠç°
æ°ŽçŽ åå7HïŒ4Hã¢ãŒãã«ïŒ å®æœäŸ ïŒ ïŒåŒïŒïŒã®ååç©ã®ïŒ¬âãªãžã³å¡©ïŒ åºçºç©è³ªãšããŠãšã¿ããŒã«ã¢ãã³ã®ãããã«ïŒ¬
âãªãžã³ãçšããã»ãã¯å®æœäŸïŒãšåæ§ã®æ¹æ³ã«
ããâãªãžã³å¡©ããããèç¹ã¯193ã196âã§ã
ã€ãã å çŽ åæå€ïŒC21H26F2N2O5ïŒååé424.43
ãšããŠïŒ çè«å€ïŒïŒ ïŒïŒC59.42 H6.17 N6.60 å®æž¬å€ïŒïŒ ïŒïŒC59.38 H6.23 N6.44 ïŒé®ç掻æ§ïŒ é®ç掻æ§ã¯ããŠã¹ãçšããããšãã«ããã³ã«ã
ãèªçºãããæ©è»¢è©Šéšã«ãã調ã¹ããããšãã«ã
ãã³æäžå30åã«å®éšåç©ã«å¯ŸãMR714ã®25
mgïŒKgäœéãçµå£æäžãããå¯Ÿç §äŸãšããŠã¢ã»ã
ã«ãµãªãã«é žãã€ãããããšã³ããã©ã»ã¿ã¢ãŒã«
ïŒïœâã¢ã»ãã«ã¢ããããšããŒã«ïŒããã³ãžãã«
ãã¶ãŒã«ïŒdifunisalïŒã第ïŒè¡šã«ç€ºãæäžéã§æ
äžããã ããããçµæã第ïŒè¡šã«ç€ºãã MR714ã®é®ç掻æ§ã¯å®è³ªçã«ãžãã«ãã¶ãŒã«
ãšåçã§ãããæäžéãšããŠïŒåéãçšãããã©
ã»ã¿ã¢ãŒã«ããå®è³ªçã«ããããŠãããŸã10åé
ãçšããã¢ã»ãã«ãµãªãã«é žããã³ïŒåéãçšã
ãã€ãããããšã³ãšãã®æŽ»æ§ãå®è³ªçã«åãã§ã
ãé«ãé®ç掻æ§ãæããããšãå€æããã ïŒæçç掻æ§ïŒ è©Šéšã¯ã©ãããçšãMR714ã®25mgïŒKgäœéçµ
å£æäžãããå¯Ÿç §äŸãšããŠã¢ã»ãã«ãµãªãã«é žã
ã€ãããããšã³ããã©ã»ã¿ã¢ãŒã«ããã³ãžãã«ã
ã¶ãŒã«ãçšãããæäž30ååŸãã«ã©ã²ãã³ãµãã
ã©ã³ã¿ïŒsubplantarïŒæ³šå°ã«ãã浮皮ãå®éšåç©
ã®å³è¶³ã«çãããããã®ççéšåã®äœç©ãïŒæé
ããšã«ïŒæéã«ãããèšé²ããã ããããçµæã第ïŒè¡šã«ç€ºãã ãã®çµæãMR714ãããããæçç掻æ§ãæ
ããããšãå€æããã ïŒèèæ§è©ŠéšïŒ æççéã¹ããã€ãå€ã®å€ããèç²èã«é害ã
ã²ããããããšããMR714ã®èèæ§è©Šéšãå®æœ
ããã 18æé絶é£ãããã©ããã«MR714ãçµå£æäž
ããå¯Ÿç §äŸãšããŠã¢ã»ãã«ãµãªãã«é žãã€ããã
ããšã³ããã©ã»ã¿ã¢ãŒã«ããã³ãžãã«ãã¶ãŒã«ã
çšããã æäžéãšããããçµæã第ïŒè¡šã«ç€ºãã æäžïŒæéåŸã®çµæããMR714ã¯èç²èã«å¯Ÿ
ããŠååãªèæ§ãããããšãå€æããã第ïŒè¡šã
ããMR714ã¯å®è³ªçã«èé害ãæ¹ãèµ·ããã察
ç §äŸãšæ¯èŒããŠããã®çšåºŠãããªãäœãããšãã
ããã ïŒæ¥æ§æ¯æ§è©ŠéšïŒ MR714ã¯ã»ãšãã©æ¥æ§æ¯æ§ããªãããšãå€æ
ãããããŠã¹ã«å¯ŸããŠçµå£æäžããŠè¡ãªã€ãæ¥æ§
æ¯æ§è©Šéšã«ãããŠãDL50ã¯840mgïŒKgäœéã§ãã€
ãã ïŒè¬çåŠè©Šéšããã³ä»£è¬ïŒ è©Šéšã¯ã©ãããçšããŠè¡ãªãã25ïŒ50ããã³
100mgïŒKgäœéã®MR714ãçµå£æäžãããè¡æŒ¿äž
ã®MR714ã®æ¿åºŠãå¢å ããæäžåŸïŒæéãªãã
ïŒæéã§æåã®ããŒã¯ã«å¯ŸããããããŠãã®æ¿åºŠ
ã次第ã«äœäžãã第ïŒã®ããŒã¯ãçŸãããã50ãª
ãã100mgïŒKgæäžããã°ããã«ã¯24æéæç¶ã
ãé·æéã®ãã©ãïŒplateauïŒããŒã¯ãçãã
ãã25mgïŒKgäœéæäžããå Žåã«ã¯ç¬¬ïŒã®ããŒã¯
ã¯çæéã§æ¶æ» ããã è¡æŒ¿äžã«ãããåæžæã¯13æéã§ãããããã¯
ä»ã®æççéã¹ããã€å€ãšæ¯èŒããŠé«ãæ°å€ã§ã
ãããŸãå¯Ÿç §äŸãšæ¯èŒããŠããžãã«ãã¶ãŒã«ã®å
æžæïŒæäžéãåãã§ããã°ããïŒã®ïŒå匷ã§ã
ããããMR714ã®æçšéã¯ïŒæ¥ïŒåã§é©åœã§ã
ãã èèµãè èµãèºããã³åå®®ã«ãããæ¿åºŠã¯è¡æŒ¿
äžã«ãããæ¿åºŠãšæ¯èŒããŠäœããç°ãªãæ æ§ã瀺
ãããããããªãããè¡æŒ¿ãšåå®®ã®æ¿åºŠæ¯ã¯0.34
ã§ããããªãé«ãæ°å€ã§ããã ïŒååç©ïŒïŒããã³ãã®å¡©ã®è£œå€æ³ïŒ çµå£ãããã¯éçµå£æäžãããæ¬çºæã®å»è¬çµ
æç©ã®ããã¡ãšããŠã¯ãããšãã°æ¡æ£å¯èœãªãã
ããã¯å è£ çŽã«ããããã±ãŒãžå¯èœãªé å€ãã«ã
ã»ã«ãç²æ«ãªã©ãé©åœã§ããã泚å°è¬ãšããŠãã
ã¢ãŒã«ïŒphthialsïŒãé©åœã§ããã 以äžã«åŠæ¹äŸããããŠèª¬æãããæ¬çºæã¯ãã
ãã®åŠæ¹äŸã®ã¿ã«éå®ããããã®ã§ã¯ãªãã åŠæ¹äŸ ïœ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é ž250mgã«è£œè¬æ¥çã§äžè¬ã«
çšããããŠãã賊圢å€ãšæ¡æ£å€ãé åãé å€ãš
ããã ïœ åŒïŒïŒã§è¡šãããããªãã·ããããªã³é žèª
å°äœ375mgã«äžè¿°ã®è³Šåœ¢å€ãšæ¡æ£å€ãæ·»å ãé
å€ãšããã ïœ èŠªæ¶²æ§ã§ããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâã
ããšãã«ïŒâãªãã·ããããªã³é žã®ãªãžã³å¡©400
mgã«çèå 泚å°çšã®æº¶åªãšããŠçŽ3ccã®ããã¢
ãŒã«ãå ããŠæ³šå°æ¶²ãšããã ïŒäººäœã«å¯Ÿããæå¹æäžéïŒ æ¬çºæã®ååç©ã¯æ人æ£è ã«ïŒæ¥ããã250ã
750mgæäžå¯èœã§ãããããªãã¡250mgã®é å€ãïŒ
æ¥ãããïŒãªããïŒããããã¯375mgã®é å€ãïŒ
æ¥ãããïŒãªããïŒæäžå¯èœã§ããã
ãè¡šã
ãè¡šã
ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒïŒïŒ ã§è¡šããããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããš
ãã«ïŒâãªãã·ããããªã³é žãŸãã¯ãã®éå±ãã
ãã¯ææ©å¡©åºã«ããå¡©ã ïŒ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é žã®ãããªãŠã å¡©ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é žã®ã«ã«ã·ãŠã å¡©ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é žã®ãªãžã³å¡©ã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é žã®ã¢ã«ã®ãã³å¡©ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ ïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããšãã«ïŒâ
ãªãã·ããããªã³é žã®ãšã¿ããŒã«ã¢ãã³å¡©ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ååç©ã ïŒ åŒïŒïŒ ã§è¡šããããïŒâïŒ2â²ïŒ4â²âãžãã«ãªãããšã
ã«ïŒããšããŒã«ã®ãããªãŠã å¡©ãšãåŒïŒïŒïŒ ã§è¡šããããããã¢ããããªã³é žãšãã«ãšãåå¿
ãããã€ãã§ããããåŒïŒïŒïŒ ã§è¡šãããããšã¹ãã«ååç©ãå æ°Žå解ããããš
ãç¹åŸŽãšããåŒïŒïŒïŒ ã§è¡šããããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããš
ãã«ïŒâãªãã·ããããªã³é žã®è£œé æ³ã ïŒ åŒïŒïŒïŒ ã§è¡šããããïŒ2â²ïŒ4â²âãžãã«ãªãâïŒâãããš
ãã«ïŒâãªãã·ããããªã³é žãŸãã¯ãã®è¬çåŠç
ã«èš±å®¹ãããå¡©ãæå¹æåãšããé®çæ¶çå€ã ïŒ çµå£æäžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããŠããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®é®çæ¶çå€ã ïŒïŒ éçµå£æäžã«å¥œé©ãªåœ¢æ ã«è£œå€ãããŠãªã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®é®çæ¶çå€ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT8125243A IT1211135B (it) | 1981-11-24 | 1981-11-24 | Composti ad attivita'analgesica e antiinfiammatoria, processo per la loro preparazione e relative composizioni farmaceutiche. |
IT25243A/81 | 1981-11-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5892636A JPS5892636A (ja) | 1983-06-02 |
JPS6124374B2 true JPS6124374B2 (ja) | 1986-06-10 |
Family
ID=11216107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57086379A Granted JPS5892636A (ja) | 1981-11-24 | 1982-05-20 | ãªãã·ããããªã³é žèªå°äœããã®è£œæ³ããã³ãããæå¹æåãšããé®çæ¶çå€ |
Country Status (13)
Country | Link |
---|---|
US (1) | US4440787A (ja) |
EP (1) | EP0080010B1 (ja) |
JP (1) | JPS5892636A (ja) |
KR (1) | KR830010038A (ja) |
AR (1) | AR230422A1 (ja) |
AT (1) | ATE14720T1 (ja) |
CA (1) | CA1185617A (ja) |
DE (1) | DE3265210D1 (ja) |
ES (1) | ES8302623A1 (ja) |
GR (1) | GR75481B (ja) |
IT (1) | IT1211135B (ja) |
PT (1) | PT74937A (ja) |
ZA (1) | ZA823487B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83109A (en) * | 1986-07-11 | 1992-06-21 | Ciba Geigy Ag | Guanidinium aspartates,their preparation and pharmaceutical compositions containing them |
US4883818A (en) * | 1987-11-17 | 1989-11-28 | Analgesic Associates | Onset-hastened/enhanced analgesia |
US4927854A (en) * | 1987-12-24 | 1990-05-22 | Analgesic Associates | Sustained/enhanced analgesia |
US5286751A (en) * | 1987-12-24 | 1994-02-15 | Analgesic Associates | Sustained/enhanced antipyretic response |
ES2079997A1 (es) * | 1993-06-15 | 1996-01-16 | Lilly Co Eli | Compuestos de fenil fenol sustituidos antagonistas de leucotrieno, procedimiento para su obtencion y formulaciones farmaceuticas de los mismos. |
MX2015016543A (es) * | 2013-06-27 | 2017-07-27 | Lg Chemical Ltd | Derivados de biarilo como agonistas de gpr120. |
CA3121986C (en) * | 2014-12-24 | 2024-04-09 | Lg Chem, Ltd. | Biaryl derivative as gpr120 agonist |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1121722A (en) * | 1966-03-31 | 1968-07-31 | Ici Ltd | New carboxylic acid derivatives |
US3755603A (en) * | 1970-07-01 | 1973-08-28 | Syntex Corp | Biphenylyloxyacetic acids in pharmaceutical compositions |
US4021479A (en) * | 1971-03-17 | 1977-05-03 | Boehringer Ingelheim Gmbh | Derivatives of 4-(4-biphenylyl)-butyric acid |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
GB1459084A (en) * | 1973-05-24 | 1976-12-22 | Boots Co Ltd | Preparation of arylalkanoic acid |
US4188491A (en) * | 1975-04-04 | 1980-02-12 | The Boots Company Limited | Preparation of therapeutic compounds |
US4151302A (en) * | 1975-06-28 | 1979-04-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Araliphatic dihalogen compounds composition and method of use |
US4189499A (en) * | 1977-03-16 | 1980-02-19 | Biochefarm S.A. | Lysine 4-allyloxy-3-chlorophenylacetate and method of its preparation |
US4225730A (en) * | 1978-05-11 | 1980-09-30 | Merck & Co., Inc. | Process for preparing 4-(2,4-difluorophenyl)-salicyclic acid |
JPS5576840A (en) * | 1978-12-01 | 1980-06-10 | Kaken Pharmaceut Co Ltd | New oxyacetic acid derivative, its preparation and blood- lipid depressor containing it as active principle |
IT1141655B (it) * | 1980-02-12 | 1986-10-08 | Schiapparelli Spa | Nuovi derivati dell'acido propanoico ad attivita' ipolipidemica e ipocolesterolemica |
-
1981
- 1981-11-24 IT IT8125243A patent/IT1211135B/it active
-
1982
- 1982-05-19 AT AT82104415T patent/ATE14720T1/de not_active IP Right Cessation
- 1982-05-19 ZA ZA823487A patent/ZA823487B/xx unknown
- 1982-05-19 EP EP82104415A patent/EP0080010B1/en not_active Expired
- 1982-05-19 DE DE8282104415T patent/DE3265210D1/de not_active Expired
- 1982-05-20 KR KR1019820002209A patent/KR830010038A/ko unknown
- 1982-05-20 AR AR289467A patent/AR230422A1/es active
- 1982-05-20 PT PT74937A patent/PT74937A/pt unknown
- 1982-05-20 CA CA000403421A patent/CA1185617A/en not_active Expired
- 1982-05-20 ES ES512387A patent/ES8302623A1/es not_active Expired
- 1982-05-20 GR GR68200A patent/GR75481B/el unknown
- 1982-05-20 US US06/380,125 patent/US4440787A/en not_active Expired - Fee Related
- 1982-05-20 JP JP57086379A patent/JPS5892636A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
US4440787A (en) | 1984-04-03 |
JPS5892636A (ja) | 1983-06-02 |
ZA823487B (en) | 1983-04-27 |
KR830010038A (ko) | 1983-12-24 |
EP0080010B1 (en) | 1985-08-07 |
CA1185617A (en) | 1985-04-16 |
DE3265210D1 (en) | 1985-09-12 |
GR75481B (ja) | 1984-07-23 |
PT74937A (en) | 1982-06-01 |
AR230422A1 (es) | 1984-04-30 |
EP0080010A1 (en) | 1983-06-01 |
IT8125243A0 (it) | 1981-11-24 |
ES512387A0 (es) | 1983-02-01 |
ATE14720T1 (de) | 1985-08-15 |
IT1211135B (it) | 1989-09-29 |
ES8302623A1 (es) | 1983-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62230722A (ja) | è¥æºããã³ïŒãŸãã¯é¢é£ç¶æ ã®æ²»çå€ | |
KR100422276B1 (ko) | ì¹íë칎복ì€ì°ííìììŽìšì±ë¹ë§ì·šì±ì§íµì ì몚륎íìŒë°ëì몚륎íìŒ,ìŽë€ìì ì¡°ë°©ë²,ìŽë€ìì©ëë°ìŽë€ìŒìí¬íšíëì ì | |
JPS6033818B2 (ja) | æ°ããã¿ã¬ã³èªå°äœã®è£œæ³ | |
JPH059424B2 (ja) | ||
JPH0788352B2 (ja) | ããããã·ã¢ã«ãã«ã·ã¹ãã€ã³èªå°äœããã³ãããå«æããå»ç°å€ | |
JPS6124374B2 (ja) | ||
CN108395437B (zh) | æ°ä»£ååç©åå ¶å»è¯çšé | |
WO1990002724A1 (en) | SUBSTITUTED β-DIKETONES | |
JPH0234951B2 (ja) | ||
JPS58121274A (ja) | ïŒâãã§ãã«âã·ã¯ããã³ã¿ã³ã«ã«ãã³é žã®ïœâããªãžã«âã¢ããããã®è£œé æ³ãªãã³ã«ãããæå¹æåãšããæ¶çããã³é®å³å€ | |
JPH0365338B2 (ja) | ||
JPH037670B2 (ja) | ||
JPS6124375B2 (ja) | ||
GB1560239A (en) | Substituted phenylglycolic acid and its pharmacetuically acceptable esters and salts and processes for preparing the same | |
JPH0474354B2 (ja) | ||
JPS6033373B2 (ja) | ïŒâãããã«é ¢é žèªå°äœããã®è£œé æ³ãªãã³ã«ïŒâãããã«é ¢é žèªå°äœãå«æããè¬å€ | |
JPH0692948A (ja) | æ°èŠãªã¢ã»ã¿ããèªå°äœåã³ãã®çšé | |
JPS6056142B2 (ja) | ãã¢ãŸãªã³ã®æ°èŠèªå°äœããã³ãã®å»è¬ãšããŠã®é©çš | |
JPS609752B2 (ja) | æ°èŠãªïŒâã¢ã»ããã·ãã³ãºã¢ããèªå°äœããã®è£œæ³åã³ãããæå¹æåãšããå»è¬ | |
JPS6218543B2 (ja) | ||
US4156009A (en) | Diazepine derivatives | |
HU182916B (en) | Process for preparing 1,3-benzoxazine-2,4-dione derivatives | |
JPS6152822B2 (ja) | ||
GB2102797A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes | |
US3708581A (en) | Anti-inflammatories |